Shelonitda Rose

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Philippe Armand, Margaret A. Shipp, Vincent Ribrag et al. · Journal of Clinical Oncology · 2016 · 672 citations

Medicine, Hematology, Oncology +17

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With <i>TP53</i>-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

Suzanne Leijen, Robin M.J.M. van Geel, Gabe S. Sonke et al. · Journal of Clinical Oncology · 2016 · 343 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

Suzanne Leijen, Robin M.J.M. van Geel, Anna C. Pavlick et al. · Journal of Clinical Oncology · 2016 · 269 citations · Full text

Medicine, Oncology, Pharmacology +14

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini et al. · The Lancet · 2023 · 164 citations · Full text

Medicine, Hematology, Pharmacology +14

PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)

Craig H. Moskowitz, Vincent Ribrag, Jean‐Marie Michot et al. · Blood · 2014 · 154 citations

Life Sciences, Immunology, Oncology +17